IART
Integra Lifesciences Holdings·NASDAQ
--
--(--)
--
--(--)
IART fundamentals
Integra Lifesciences Holdings (IART) released its earnings on Feb 26, 2026: revenue was 434.93M (YoY -1.74%), beat estimates; EPS was 0.83 (YoY -14.43%), beat estimates.
Revenue / YoY
434.93M
-1.74%
EPS / YoY
0.83
-14.43%
Report date
Feb 26, 2026
IART Earnings Call Summary for Q4,2025
- Revenue Resilience: Q4 2025 revenue $435 million, adjusted EPS $0.83, beating guidance. Full-year 2025 organic growth constrained by supply but demand strong.
- 2026 Growth Drivers: Braintree facility launch in Q2 2026 to enable SurgiMend relaunch. CMS changes align with portfolio, pricing within new reimbursement ranges.
- Financial Improvement: 2026 free cash flow expected to exceed $200 million, up $150 million from 2025, driven by reduced capital spending and operational efficiency.
- Tariff Uncertainty: 2026 guidance excludes potential Section 122 tariff recovery, with 2025 tariffs impact of $0.32 per share.
EPS
Actual | 0.48 | 0.33 | 0.8 | 0.84 | 0.69 | 0.79 | 0.86 | 0.84 | 0.74 | 0.82 | 0.86 | 0.94 | 0.74 | 0.71 | 0.76 | 0.89 | 0.55 | 0.63 | 0.41 | 0.97 | 0.41 | 0.45 | 0.54 | 0.83 | ||||||||||
Forecast | 0.6221 | 0.0897 | 0.5427 | 0.7329 | 0.5655 | 0.6587 | 0.7244 | 0.8408 | 0.6833 | 0.7993 | 0.7203 | 0.9036 | 0.7376 | 0.5693 | 0.7784 | 0.903 | 0.552 | 0.6235 | 0.3901 | 0.854 | 0.4311 | 0.4362 | 0.4342 | 0.8002 | ||||||||||
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -22.84% | +267.89% | +47.41% | +14.61% | +22.02% | +19.93% | +18.72% | -0.10% | +8.30% | +2.59% | +19.39% | +4.03% | +0.33% | +24.71% | -2.36% | -1.44% | -0.36% | +1.04% | +5.10% | +13.58% | -4.89% | +3.16% | +24.37% | +3.72% |
Revenue
Actual | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 354.32M | 258.67M | 370.23M | 388.65M | 360.07M | 389.99M | 386.86M | 405.52M | 376.64M | 397.81M | 385.19M | 398.02M | 380.85M | 381.27M | 382.42M | 397.04M | 368.87M | 418.18M | 380.83M | 442.64M | 382.65M | 415.61M | 402.06M | 434.93M |
Forecast | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 359.84M | 243.82M | 351.65M | 389.06M | 349.78M | 376.11M | 384.62M | 404.56M | 362.41M | 395.35M | 378.33M | 397.92M | 373.23M | 374.01M | 387.22M | 399.34M | 363.74M | 413.07M | 375.81M | 445.11M | 381.20M | 395.00M | 414.23M | 429.63M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1.53% | +6.09% | +5.28% | -0.11% | +2.94% | +3.69% | +0.58% | +0.24% | +3.93% | +0.62% | +1.81% | +0.02% | +2.04% | +1.94% | -1.24% | -0.58% | +1.41% | +1.24% | +1.34% | -0.55% | +0.38% | +5.22% | -2.94% | +1.23% |
Earnings Call
You can ask Aime
What is Integra Lifesciences Holdings's gross profit margin?What were the key takeaways from Integra Lifesciences Holdings's earnings call?What guidance did Integra Lifesciences Holdings's management provide for the next earnings period?What is Integra Lifesciences Holdings's latest dividend and current dividend yield?What is the market's earnings forecast for Integra Lifesciences Holdings next quarter?What factors drove the changes in Integra Lifesciences Holdings's revenue and profit?What does Integra Lifesciences Holdings do and what are its main business segments?What were the key takeaways from Integra Lifesciences Holdings’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
